By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Drugs and Therapies - Antiretrovirals. According to news reporting originating from Paris, France, by NewsRx correspondents, research stated, “Assessment of virological outcomes among HIV-infected patients receiving protease (PR) inhibitor-based second-line regimen are uncommon in Cambodia. The objective of this study is to assess the virological effectiveness of this regimen as well as impact of adherence boosting for patients experiencing virological failure.”
Financial support for this research came from Agence Nationale de Recherches sur le Sida et les Hepatites Virales.
Our news editors obtained a quote from the research, “The 2PICAM study (Clinicaltrial: NCT01801618) is a cross-sectional study of HIV-infected adults on PR inhibitor-based second-line regimen since at least 6 months, conducted in 13 representative sites, comprising more than 90% of the target population. Adults with HIV RNA above 250 copies/mL (threshold of the assay) at inclusion received boosted adherence counseling during 3 months followed by HIV RNA control. For confirmed virological failure, genotype resistance test was performed and expert committee used results for therapeutic decision. Among the 1,317 adults enrolled, the median duration of second-line regimen was 5 years. At inclusion, 1,182 (89.7%) patients achieved virological success (<250 copies/mL) and 135 (10.3%) experienced a virological failure (>250 copies/mL). In multivariable analysis, factors associated with virological success were: CD4 cell count between 201 and 350/mm (OR: 4.66, 95% CI: 2.57-8.47, <0.0001) and >350/mm (OR: 6.67, 95% CI: 4.02-11.06, <0.0001), duration of PI-based regimen >2 years (OR: 1.64, 95% CI: 1.03-2.62,=0.037), ATV-containing regimen (0R: 1.65, 95% CI: 1.04-2.63,=0.034) and high level of adherence (OR: 2.41, 95% CI: 1.07-5.41,=0.033). After adherence counseling, 63 (46.7%) patients were rescued while 72 (53.3%) were not. For the 54 patients with genotype resistance tests available, high or intermediate levels of resistance to lopinavir, atazanavir, and darunavir were reported for 13 (24%), 12 (22.2%), and 2 (3.7%) patients, respectively. Change to an alternative PR inhibitor-based regimen was recommended for 17 patients and to third-line regimen, including integrase inhibitors for 12. This study reports high rate of virological suppression of second-line regimen and importance of adherence boosting prior to deciding any change of ART regimen. Genotype resistance tests appear necessary to guide decisions.”
According to the news editors, the research concluded: “Such information was of great importance for National HIV Program to adapt guidelines and program needs for third-line regimen.”
For more information on this research see: Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study. Frontiers In Public Health , 2018;6():63.
The news editors report that additional information may be obtained by contacting O. Segeral, French Agency for Research on AIDS and Viral Hepatitis (ANRS), Paris, France. Additional authors for this research include E. Nerrienet, S. Neth, B. Spire, V. Khol, L. Ferradini, S. Sarun, C. Mom, S. Ngin, C. Charpentier, P. Men, M. Mora, V. Mean Chhi, P. Ly and V. Saphonn.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.3389/fpubh.2018.00063. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
CITATION: (2018-05-02), Data on Antiretrovirals Detailed by O. Segeral and Co-Authors (Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study), Biotech Week, 114, ISSN: 1537-4699, BUTTER® ID: 015569994
From the newsletter Biotech Week.
https://www.newsrx.com/Butter/#!Search:a=15569994
This is a NewsRx® article created by NewsRx® and posted by NewsRx®. As proof that we are NewsRx® posting NewsRx® content, we have added a link to this steemit page on our main corporate website. The link is at the bottom left under "site links" at https://www.newsrx.com/NewsRxCorp/.
We have been in business for more than 20 years and our full contact information is available on our main corporate website.
We only upvote our posts after at least one other user has upvoted the article to increase the curation awards of upvoters.
NewsRx® offers 195 weekly newsletters providing comprehensive information on all professional topics, ranging from health, pharma and life science to business, tech, energy, law, and finance. Our newsletters report only the most relevant and authoritative information from qualified sources.